Pharmasaga is an Academia Sinica-derived biotech company, and focus on the development of a first-in-class diabetes drug, PS001. PS001 is an inhibitor of PDIA4 protein, which plays a critical role in diabetes development. Oral administration of PS001 in diabetic mice can prevent the beta cell death through ROS decreasing, stabilize the blood sugar and reverse diabetes. The preclinical studies and CMC had been completed. The US IND of PS001 had been approved in 2022Q1, and the Phase I clinical trial will be launched in 2022Q2.